Market Cap : 1.73 B | Enterprise Value : 1.89 B | P/E (TTM) : | P/B : 0.91 |
---|
OPK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OPK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
vs
industry |
vs
history |
||
---|---|---|---|
Cash-to-Debt | 0.21 |
74% of the 859 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.03 vs. OPK: 0.21 ) Ranked among companies with meaningful Cash-to-Debt only. |
OPK'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: 6.97 Max: No Debt Current: 0.21 |
Equity-to-Asset | 0.72 |
65% of the 788 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.64 vs. OPK: 0.72 ) Ranked among companies with meaningful Equity-to-Asset only. |
OPK'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41 Med: 0.7 Max: 0.96 Current: 0.72 |
Debt-to-Equity | 0.12 |
75% of the 596 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.32 vs. OPK: 0.12 ) Ranked among companies with meaningful Debt-to-Equity only. |
OPK'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.44 Med: 0.1 Max: 38.41 Current: 0.12 |
Piotroski F-Score: 1 |
|
Altman Z-Score: 0.99 |
|
Beneish M-Score: -3.22 |
|
WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
vs
industry |
vs
history |
||
---|---|---|---|
Operating Margin % | -25.59 |
80% of the 801 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.97 vs. OPK: -25.59 ) Ranked among companies with meaningful Operating Margin % only. |
OPK'
s Operating Margin % Range Over the Past 10 Years
Min: -393.7 Med: -76.43 Max: -4.61 Current: -25.59 |
Net Margin % | -30.23 |
79% of the 802 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.32 vs. OPK: -30.23 ) Ranked among companies with meaningful Net Margin % only. |
OPK'
s Net Margin % Range Over the Past 10 Years
Min: -421.97 Med: -56.54 Max: -2.05 Current: -30.23 |
ROE % | -15.48 |
74% of the 832 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.94 vs. OPK: -15.48 ) Ranked among companies with meaningful ROE % only. |
OPK'
s ROE % Range Over the Past 10 Years
Min: -467.26 Med: -18.57 Max: -1.23 Current: -15.48 |
ROA % | -11.28 |
73% of the 871 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.88 vs. OPK: -11.28 ) Ranked among companies with meaningful ROA % only. |
OPK'
s ROA % Range Over the Past 10 Years
Min: -129.9 Med: -12.23 Max: -0.83 Current: -11.28 |
ROC (Joel Greenblatt) % | -135.73 |
80% of the 855 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 11.23 vs. OPK: -135.73 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
OPK'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6953.23 Med: -169.39 Max: -43.73 Current: -135.73 |
3-Year Revenue Growth Rate | 106.80 |
99% of the 689 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.80 vs. OPK: 106.80 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
OPK'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0 Med: 24.65 Max: 174.6 Current: 106.8 |
3-Year EBITDA Growth Rate | 4.40 |
56% of the 704 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.30 vs. OPK: 4.40 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
OPK'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0 Med: -6.55 Max: 45.5 Current: 4.4 |
3-Year EPS without NRI Growth Rate | -10.30 |
76% of the 663 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 8.90 vs. OPK: -10.30 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
OPK'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -152.4 Med: 5.45 Max: 69.4 Current: -10.3 |
Charles Brandes 664,840 sh (New) Murray Stahl 124,459 sh (+59.52%) Jim Simons 370,401 sh (+131.51%) Mario Gabelli 88,800 sh (+2.30%) | Ken Fisher Sold Out |
Jim Simons Sold Out Charles Brandes 590,197 sh (-11.23%) Murray Stahl 92,897 sh (-25.36%) Mario Gabelli 77,800 sh (-12.39%) |
Jim Simons 29,043 sh (New) Paul Tudor Jones 134,365 sh (New) | Mario Gabelli 77,800 sh (unchged) | Charles Brandes Sold Out Murray Stahl Sold Out |
Jim Simons Sold Out Mario Gabelli 76,000 sh (-2.31%) Paul Tudor Jones 133,517 sh (-0.63%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
Guru | Date | Action |
Impact | Price Range (Average)* |
Change from Average | Comment | Current Shares |
---|
Industry: | Drug Manufacturers » Drug Manufacturers - Specialty & Generic NAICS: 325412 SIC: 2834 | |
---|---|---|
Compare: | NAS:PAHC, NAS:AKRX, SHSE:603567, HKSE:02877, TSE:8129, SZSE:300630, TSE:4555, NYSE:DPLO, XKRX:145020, NAS:MNTA, BOM:540596, BOM:532872, SHSE:600329, XKRX:041960, TSX:LEAF, SZSE:300401, SHSE:600781, BOM:533573, XKRX:003520, SZSE:002737 » details | |
Traded in other countries: | XCY.Germany, OPK.Israel, OPK.Mexico, | |
Headquarter Location: | USA |
vs
industry |
vs
history |
||
---|---|---|---|
PB Ratio | 0.91 |
70% of the 819 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.64 vs. OPK: 0.91 ) Ranked among companies with meaningful PB Ratio only. |
OPK'
s PB Ratio Range Over the Past 10 Years
Min: 0.8 Med: 7.52 Max: 800 Current: 0.91 |
PS Ratio | 1.60 |
50% of the 775 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.10 vs. OPK: 1.60 ) Ranked among companies with meaningful PS Ratio only. |
OPK'
s PS Ratio Range Over the Past 10 Years
Min: 1.49 Med: 28.43 Max: 158.13 Current: 1.6 |
EV-to-Revenue | 1.94 |
50% of the 795 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.24 vs. OPK: 1.94 ) Ranked among companies with meaningful EV-to-Revenue only. |
OPK'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.7 Med: 29.6 Max: 161.4 Current: 1.94 |
Current Ratio | 0.91 |
85% of the 855 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.39 vs. OPK: 0.91 ) Ranked among companies with meaningful Current Ratio only. |
OPK'
s Current Ratio Range Over the Past 10 Years
Min: 0.88 Med: 4.6 Max: 415 Current: 0.91 |
Quick Ratio | 0.78 |
79% of the 855 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.87 vs. OPK: 0.78 ) Ranked among companies with meaningful Quick Ratio only. |
OPK'
s Quick Ratio Range Over the Past 10 Years
Min: 0.48 Med: 4.09 Max: 415 Current: 0.78 |
Days Inventory | 28.19 |
92% of the 755 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 119.80 vs. OPK: 28.19 ) Ranked among companies with meaningful Days Inventory only. |
OPK'
s Days Inventory Range Over the Past 10 Years
Min: 25.94 Med: 142.26 Max: 352.41 Current: 28.19 |
Days Sales Outstanding | 59.70 |
72% of the 770 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 81.76 vs. OPK: 59.70 ) Ranked among companies with meaningful Days Sales Outstanding only. |
OPK'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86 Med: 105.9 Max: 243.4 Current: 59.7 |
Days Payable | 39.15 |
78% of the 758 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 76.32 vs. OPK: 39.15 ) Ranked among companies with meaningful Days Payable only. |
OPK'
s Days Payable Range Over the Past 10 Years
Min: 31.85 Med: 101.87 Max: 182.52 Current: 39.15 |
vs
industry |
vs
history |
||
---|---|---|---|
3-Year Average Share Buyback Ratio | -9.00 |
60% of the 571 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: -5.30 vs. OPK: -9.00 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
OPK'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3 Med: -13.85 Max: 0.4 Current: -9 |
vs
industry |
vs
history |
||
---|---|---|---|
Price-to-Intrinsic-Value-Projected-FCF | 1.91 | ||
Price-to-Median-PS-Value | 0.06 |
99% of the 743 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.94 vs. OPK: 0.06 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
OPK'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.06 Med: 1.41 Max: 30 Current: 0.06 |
Earnings Yield (Greenblatt) % | -11.39 |
81% of the 867 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.31 vs. OPK: -11.39 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
OPK'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -25.6 Med: -3.25 Max: 0.5 Current: -11.39 |
Revenue (TTM) (Mil) $ | 962.11 |
---|---|
EPS (TTM) $ | -0.53 |
Beta | 1.77 |
Volatility | 73.65% |
52-Week Range $ | 2.34 - 6.40 |
Shares Outstanding (Mil) | 615.58 |
Dec18 | Dec19 | Dec20 | Dec21 | |
---|---|---|---|---|
Revenue (Mil $) | 1,008 | 1,026 | 1,141 | 1,357 |
EBIT (Mil $) | ||||
EBITDA (Mil $) | ||||
EPS ($) | -0.20 | -0.18 | -0.03 | 0.11 |
EPS without NRI ($) | -0.20 | -0.18 | -0.03 | 0.11 |
EPS Growth Rate (Future 3Y To 5Y Estimate) | 12.00% | |||
Dividends per Share ($) |
|
GF Chat